Highlights

  • CHM shares fell A$0.02 (-10.00%) to A$0.18 on May 1, 2026, on Volume of 271,910 shares
  • CHM CDH17 program advanced to Dose Level 3 (450 million cells) with no safety concerns; CART+ cells detected in patient blood for more than 12 months
  • CORE-NK Phase 1b trial achieved a 60% CR/CRi rate across 25 enrolled AML patients at MD Anderson Cancer Center

 

Shares in Chimeric Therapeutics Limited (ASX:CHM) declined A$0.02, or 10.00%, to trade at A$0.18 during the May 1, 2026 session, on Volume of 271,910 shares. The significant percentage decline reflects the sensitivity of micro-cap biotech stocks to market sentiment and funding concerns, even when clinical data appears constructive. The bid/offer range of A$0.165 to A$0.180 indicates that selling pressure was present, though buyers remained active.

The market's reaction to Chimeric's March 2026 Quarterly Report — released April 29, 2026 — appears to reflect a tension that is common in early-stage clinical stage companies: meaningful clinical progress alongside constrained financial resources. With cash of just A$1.75 million at March 31, 2026, the near-term funding position is the primary concern dominating investor sentiment, even as the company's clinical programs deliver data points that would typically be viewed favourably in a better-capitalised entity.

CHM CDH17 Program: Advancing to Dose Level 3

The company's flagship CHM CDH17 CAR T-cell therapy program advanced to Dose Level 3 during the quarter, with patients now receiving 450 million CDH17 CART+ cells. Dose Levels 1 and 2 were completed with no safety concerns or off-target effects observed — a critical early finding for any CAR T-cell therapy, given the potential for cytokine release syndrome and on-target, off-tumour effects that have historically complicated the development of similar therapies.

Eleven successful Manufacturing runs have been completed, an important operational milestone given that Manufacturing complexity is one of the persistent challenges for autologous cell therapy programs. Of particular note is the persistence data: CHM CDH17 CART+ cells have been detected in patients' blood for more than 12 months — an exceptional duration that signals durable immune cell engraftment and may translate into sustained clinical benefit.

Among patients enrolled, one colorectal cancer (CRC) patient has experienced stable disease for 13 months from a single dose at Dose Level 1, while another CRC patient has experienced stable disease ongoing at 9 months from a single dose at Dose Level 2. Neither patient has required any other therapies during this period. The combination of clinical expansion, persistence data, and the absence of gastrointestinal toxicity or off-tumour effects is described by management as significantly de-risking the CHM CDH17 program. The Phase 1 portion of the study is expected to enrol up to 15 patients before dose selection and expansion into indication-specific Phase 2 cohorts.

CORE-NK Phase 1b: 60% Complete Response Rate in AML

Subsequent to the end of the March quarter, Chimeric announced new clinical data from the ADVENT-AML clinical trial, with 60% of 25 enrolled patients (15 out of 25) achieving a Complete Response or Complete Response with incomplete count recovery (CR/CRi). The trial is evaluating CHM CORE-NK in combination with azacitidine and venetoclax — a current standard of care — in high-risk acute myeloid leukaemia (AML) patients at The University of Texas MD Anderson Cancer Center.

This investigator-initiated study has been well-tolerated by patients, with no unexpected safety findings reported. Durability of response is being assessed, and translational data including persistence and cytokine profiles are under evaluation. A 60% CR/CRi rate in this patient population — which comprises high-risk AML patients ineligible for stem cell transplant — represents a clinically significant early signal that positions CHM CORE-NK as a potentially meaningful addition to the AML treatment landscape.

Portfolio Rationalisation: Return of CHM CLTX

As part of a strategic reset, Chimeric entered into an arrangement to return to City of Hope the Chlorotoxin (CHM CLTX) CAR T-cell therapy asset that it exclusively licensed in 2020. City of Hope will assume full ownership and control of the CHM CLTX intellectual property and program. Management characterised this as a disciplined Capital management decision that aligns the company's resources with its core CHM CDH17 program, rather than spreading limited financial and operational bandwidth across multiple programs. The portfolio streamlining is consistent with common practice among small-cap biotechs operating under Capital constraints.

Corporate Leadership Changes

As part of a board refresh announced in November 2025, Dr Bradley Glover was appointed Non-Executive Chair. Dr Glover brings over 20 years of Leadership experience in global biopharmaceuticals, cell therapy, biomaterials, and life sciences, with deep expertise in cell and gene therapy and Capital formation. His appointment is intended to provide strategic guidance as the company navigates a critical clinical and financial juncture. Aaron Laurita was also appointed as Chief Financial Officer, bringing finance and commercial experience from the biotechnology sector across Australia, the United States, and Canada.

Financial Position and Funding

Chimeric held A$1.75 million in cash at March 31, 2026, down from A$2.50 million at the end of the prior quarter. Net cash outflow from Operating Activities was A$3.42 million, with 90% attributable to staff costs and Research and Development. Net financing inflows of A$2.68 million comprised A$0.93 million from a December Placement Tranche and A$1.79 million from an advance against the company's anticipated FY26 Research and Development Tax Incentive.

An A$8.4 million funding package announced in December 2025 — comprising a A$4.4 million Placement and additional components including a US$2.0 million commitment from a US-based family office — remains partially in progress, with the second Tranche subject to Shareholder approval. The EGM process to approve the second Tranche of approximately A$2.1 million (including attaching Options) was underway at the time of the Quarterly Report.

Conclusion

Chimeric Therapeutics' 10% share price decline to A$0.18 on May 1, 2026 reflects the market's sensitivity to the company's near-term funding position, even as clinical data from both the CHM CDH17 and CORE-NK programs continues to generate scientifically meaningful results. The progression to Dose Level 3 without safety concerns, exceptional CART+ cell persistence exceeding 12 months, and a 60% CR/CRi rate in AML patients at MD Anderson are material clinical data points. For investors in early-stage cell therapy companies, the path forward will depend significantly on the company's ability to secure adequate funding to progress through further dose escalation and, ultimately, into Phase 2 development — a milestone that the current cash position makes increasingly urgent.